SecBot SecBot
8-K ·Filed Aug 5, 2026

CVS

CVS HEALTH Corp
BULLISH
Impact 8/10
Horizonweeks Processed3mo ago SEC0000064803-26-000097
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The magnitude of the EPS beat (39.4%) combined with a second consecutive guidance raise signals accelerating fundamental momentum, particularly in the Health Care Benefits segment. Traders should watch for continued margin improvement in H2 2026 and monitor medical cost trends, as management maintains a cautious view on elevated cost trends and macro headwinds. The raised cash flow guidance to at least $11.5B provides significant capital return flexibility.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$99.12
T+0 close · Aug 5, 2026 · via day close
Latest settled
−8.87%
T+60 · $90.33
Vs SPY
−8.81%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 5 $99.12entry
  2. T+1 · 3mo ago −2.93%α −2.77% · $96.22
  3. T+5 · 3mo ago −4.44%α −4.79% · $94.72
  4. T+20 · 3mo ago −1.91%α −1.31% · $97.23
  5. T+60 · 19d ago −8.87%α −8.81% · $90.33
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CVS Health reported strong Q2 2026 results with total revenues of $106.1 billion (+7.3% YoY) and Adjusted EPS of $2.58, significantly beating the $1.85 consensus. The company raised full-year 2026 guidance across all key metrics, driven by continued margin recovery in the Health Care Benefits segment and broad-based operational strength. This marks a second consecutive quarter of raised guidance, reinforcing the turnaround narrative.

Key Financial Metrics

EPS
$2.58
est $1.85 · +39.5%
Revenue
$106.1B
est $100.1B · +6.0% · +7.3% YoY
Rating
strong beat
Guidance
At least $414.0 billion
raised

Key Facts

  • Q2 2026 total revenues of $106.1 billion, up 7.3% year-over-year
  • Adjusted EPS of $2.58 vs consensus of $1.85 (beat by 39.4%)
  • GAAP diluted EPS of $2.31 vs $0.80 in prior year
  • Full-year 2026 GAAP EPS guidance raised to $6.84-$7.04 from $6.24-$6.44
  • Full-year 2026 Adjusted EPS guidance raised to $7.90-$8.10 from $7.30-$7.50
  • Cash flow from operations guidance raised to at least $11.5 billion from at least $9.5 billion
  • Health Care Benefits segment adjusted operating income increased 85.5% YoY
  • Medical benefit ratio improved to 87.4% from 89.9% in prior year
  • Year-to-date cash flow from operations of $10.6 billion

Financial Impact

Full-year 2026 Adjusted EPS guidance raised by $0.60 at midpoint ($7.90-$8.10 vs prior $7.30-$7.50), representing ~8% increase

revenueepsoperating incomecash flow from operationsguidance

Risk Factors

  • Continued elevated health care cost trends could pressure margins in H2 2026
  • Potential macro headwinds and pharmacy reimbursement pressure
  • Medical membership declined 0.7M YoY due to exit from individual exchange business

Market Snapshot

Exchange
NYSE
Sector
Retail-Drug Stores and Proprietary Stores
Analyst Consensus
85% bullish (33 analysts)

Investment Themes

Consumer & Retail

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000064803-26-000097
Document: cvs-20260805.htm0000064803-26-000097
Document: 0000064803-26-000097-index-headers.html0000064803-26-000097
Document: 0000064803-26-000097-index.html0000064803-26-000097
Document: 0000064803-26-000097.txt0000064803-26-000097
8-K Data (Synthetic)0000064803-26-000097

Track record

25 reports on CVS

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +32.33% at T+60 after the Apr 8, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 13, 20264d ago Court Ruling Neutral 3/10 No price data
  2. Nov 6, 202610d ago Insider Buy Bullish 4/10 Entry $85.25 Now $88.59 +3.92% settles Dec 8
  3. Nov 4, 202612d ago 8-K Neutral 6/10 Entry $79.96 Now $88.59 +10.79% settles Dec 3
  4. Nov 4, 202612d ago 8-K Bullish 6/10 Entry $79.96 Now $88.59 +10.79% settles Dec 3
  5. Oct 26, 202621d ago Institutional Cluster Neutral 3/10 Entry $92.53 Now $88.59 −4.26% settles Nov 23
  6. Oct 15, 20264w ago Press Release Neutral 2/10 Entry $92.58 to $89.79 Now $88.59 −4.31% ▼ −3.01% −1.11% vs SPY
  7. Sep 30, 20266w ago Press Release Neutral 2/10 Entry $85.20 to $90.33 Now $88.59 +3.98% ▲ +6.02% +5.32% vs SPY
  8. Aug 5, 202614w ago 8-K Bullish 8/10 Viewing Entry $99.12 to $97.23 Now $88.59 −10.62% ▼ −1.91% −1.31% vs SPY
  9. Jul 10, 202618w ago Press Release Neutral 2/10 Entry $104.15 to $95.46 Now $88.59 −14.94% ▼ −8.35% −10.77% vs SPY
  10. Jun 29, 202620w ago Court Ruling Bullish 5/10 Entry $103.58 to $107.74 Now $88.59 −14.47% ▲ +4.02% +4.30% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens Wed (11h 11m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 5, 2026